Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

Table 1 Comparison of body weight and serum data between deferasirox and control groups

	Body weight	TP	Albumin	T-bil	AST	ALTa	ALP	BUN	CRE
	(g)	(g/dL)	(g/dL)	(mg/dL)	(IU/L)	(IU/L)	(IU/L)	(mg/dL)	(mg/dL)
Control	40.7 ± 4.1	5.6 ± 0.4	2.8 ± 0.2	0.5 ± 0.1	95.8 ± 33.9	92.3 ± 43.1	175.1 ± 23.2	25.5 ± 2.9	0.4 ± 0.1
DFX	42.8 ± 4.7	5.2 ± 0.5	2.7 ± 0.1	0.6 ± 0.3	87.6 ± 20.1	29.5 ± 13.8	162.2 ± 35.9	30.2 ± 1.6	0.6 ± 0.1

Mean ± SD.

^aP < 0.05. DFX: Deferasirox; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; BUN: Blood urea nitrogen; TP: Total protein; CRE: Creatinine.

Table 2 Patients’ characteristics

Case	Sex	Age	Etiology	Child-Pugh score (Points)	Stage1	BCLC2	Maintenance dose (mg/kg per day)	Administration period (d)	Response	AFP (ng/mL)		DCP (mAU/mL)
										Baseline	After 1 course	Baseline	After 1 course
1	M	80	HCV	B (7)	IVA	C	10	17	PD	1918	-	57	-
2	M	73	HBV	B (7)	III	C	10	35	PD	127402	260627	73	61
3	M	72	HBV	B (8)	III	B	5	248	SD	189	394	85	25
4	M	65	HBV	A (5)	IVA	C	10	28	PD	603	814	9995	16793
5	F	70	HCV	A (6)	IVA	C	15	29	PD	5580	8434	19958	15321
6	F	60	HCV	A (6)	IVA	C	15	28	PD	6172	7671	4606	2283

¹According to Liver Cancer Study Group of Japan;

²According to Barcelona Clinic Liver Cancer. HCV: Hepatitis C virus; HBV: Hepatitis B virus; AFP: Alfha-fetoprotein; DCP: Des-gamma-carboxy prothrombin. PD: Progressive disease; SD: Stable disease.

Table 3 Summary of adverse effects (mean ± SD)

Case	Creatinine at baseline (mg/dL)	eGFR at baseline (mL/min/1.73 m2)	Adverse effects (grade)	Onset time of grade 2 adverse effects
1	1.19	45.6	Elevated creatinine (3)	Week 2
			Anorexia (2)	Week 2
2	0.70	83.7	Elevated creatinine (2)	Week 2
			Anorexia (2)	Week 3
3	1.00	56.9	Elevated creatinine (2)	Week 3
4	0.75	80.2	Elevated creatinine (2)	Week 3
5	0.63	70.2	Elevated creatinine (2)	Week 4
			Anorexia (1)
6	0.43	111.5	Anorexia (1)
			Elevated creatinine (1)